Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. - Wikidata - awgldk - TriplyDB

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

http://www.wikidata.org/entity/Q35023503

about

Epigenetic treatment of solid tumours: a review of clinical trials Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia The clinical features, diagnosis and management of recurrent thymoma New and emerging HDAC inhibitors for cancer treatment A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Novel biologic therapies for thymic epithelial tumors.Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.Mutations of epigenetic regulatory genes are common in thymic carcinomas Drug monographs: belinostat and idelalisib.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update.Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Emerging treatment options for patients with recurrent advanced thymic epithelial tumors Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress.Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer 18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors Thymic malignancies: from clinical management to targeted therapies.The future of epigenetic therapy in solid tumours--lessons from the past.Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.Belinostat: clinical applications in solid tumors and lymphoma.Chemotherapy and targeted agents for thymic malignancies.Toxicological and metabolic considerations for histone deacetylase inhibitors.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Histone deacetylase inhibitors and cell death.Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Do thymic malignancies respond to target therapies?Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.

P2860

Q26773803-345F4E13-BCC8-40A5-BD0B-E0D52148AD4B Q26783014-789CE5C9-D1F9-478B-98D6-A98EE80987A0 Q27022404-7E76526B-64BB-4521-8BED-547EFD623FD7 Q27022413-968C17CC-F895-496F-802F-561E577A94D3 Q33399902-78D728F0-8F0C-4F74-AF43-2DDDD127FBCD Q33410544-F5E4EA60-848D-4057-B6EE-79B52C08EDCE Q33417499-84BDB2DB-934D-416A-89D1-1AEE1542DF4C Q33425469-6A2C4516-A592-43A9-918A-46F2091DBE61 Q33437948-08DF780E-42CD-4BE4-93BC-00DCAFB30A47 Q33605995-8C3F5DB4-6603-4306-8E93-D5163EC190A5 Q34297701-7D46FBA1-01F0-46A2-B435-CCC8DEEE8CAD Q34575453-FE2E682F-BD0F-4B21-B7D4-6DE8D84AE88B Q34648225-8CF76234-C8B5-47D1-8D9F-187649C65B89 Q35057942-6E4087AF-2A2A-4443-9820-1C8577303531 Q35214924-55E046CF-6843-41D1-9004-06AB7656FE9A Q35726371-8A6FDEEA-14A1-4F43-8FC0-56595DA6928A Q35879576-FB59CA86-A7FE-49F2-97C5-2C25D52F3DEA Q35936010-4AFB792F-6E8C-49B5-914A-A76A9F3D587E Q35939690-FA9931A5-FBB4-4947-812B-32D5DD9CFCFE Q36228352-32B573FC-B129-4FDA-86D3-49A8FEEFA5EC Q36321535-A0DCAA07-6233-426D-BDB3-3EC80A21DBEC Q36537920-0CB34479-D082-4E76-B4F6-91A2E70377C3 Q36698218-36AF0E01-D7AF-48A9-8A44-47B3CCBE6DF3 Q36910414-2FFA8C8A-49E0-4931-87E2-6EEFDF112ABC Q37061554-7BA6897C-634C-40D5-9D6F-F9CCF228308E Q37226511-627B037B-FC15-432F-AF5C-253BD9BAC17A Q37477372-6BB3155A-9D67-470A-A0FF-950BE1588F75 Q37512764-2FCCFDF7-F721-4660-B4D7-F559175CEF02 Q37638139-72C55321-4B37-42EC-8A8C-D1C3C89FF220 Q37951994-F4A22E74-A982-4DCC-B78E-50C322E13735 Q38010806-01C32B20-6B4E-4E8B-87DE-93AEA020F948 Q38071321-F2E948E6-3EF5-42B0-A8DC-C8A4754A4F0C Q38081988-F481143E-58C5-42D0-893A-D2E0170AC1F5 Q38217666-D8CDC9E5-DF69-4D18-9706-EA1FAAD9D18F Q38282448-CF04900B-7C33-4854-A751-D10C78C2C516 Q38344675-C5565B10-BA59-47A4-9D7B-7742A7158C15 Q38371199-3DEACA00-3560-4B69-B393-ECCC1F2595F1 Q38400475-60141A74-B73F-4BA3-866B-43222CB6C1B5 Q38662451-9C69458B-F457-4181-AA6C-09BAF0165C90 Q39287526-7B381A50-392B-4B23-8AE4-BDDEF0D2F473

P2860

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

http://www.wikidata.org/entity/Q35023503

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@ast

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@en

type

label

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@ast

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@en

prefLabel

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@ast

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@en

P1433

Q35023503-814CF227-7925-414D-934E-430C4AF816DE

P1476

Q35023503-7D71DE72-FB19-4DF8-A6B5-F3E38F68A7CE

P2093

Q35023503-07070623-6CB4-40AF-8EBF-C2B42B894119

Q35023503-20BC1DDA-88D6-46F1-AFF9-92F085EF00EA

Q35023503-21855500-4A92-46AB-9E5D-F22D4F4E16C8

Q35023503-24E4D74C-6161-49B7-8D65-75D32015CB70

Q35023503-5B72B5F7-5FD6-4773-A24F-A549AB6C833B

Q35023503-6847FEF0-9223-4823-B801-A7C1055E29AA

Q35023503-998ED6A8-4D0B-4040-94E9-94DE84E7BD98

Q35023503-A4EEADB1-0517-4AF8-81F1-1EDDB641866B

Q35023503-B4D5B633-E61A-4C5C-950F-9BAE5620AA32

Q35023503-D7AA9226-36C8-490E-A5E4-FB392D812968

P2860

Q35023503-0380A291-053E-41EE-BC44-8A00DFFE408B

Q35023503-0405AB3C-94D9-48C3-B9E2-1B804AD3A202

Q35023503-2724EC01-656C-4EF2-A912-6521B075D116

Q35023503-29C5787F-C5C5-4D8A-9536-1E92A4918DD4

Q35023503-3BC9E6EE-6AA7-4E37-A67F-181D905FE263

Q35023503-48AF5590-8FDC-4E80-B9D3-BA81ADDEAF75

Q35023503-5284EEAB-6BCE-449E-BA27-073C44667E04

Q35023503-53E5F16A-8603-44D0-BF5F-2AA52CDD9CEC

Q35023503-585754F2-0B75-4D12-B70B-74FC305646E7

Q35023503-78C50CAB-B84D-43F2-949E-B31BAFE68D88

P304

Q35023503-E5705868-6D44-4884-8182-B6D24EC29B6D

P31

Q35023503-AFFAE97B-2275-4399-9DCE-CE75149AB123

P356

Q35023503-8EA68FFC-77D8-4273-9EB7-8B2E04117EBC

P407

Q35023503-04451B1F-A871-4655-8F62-D13957DA4C61

P433

Q35023503-26A51375-0F7C-43FB-A6CF-34E36F39FF29

P478

Q35023503-29004653-5179-4412-87D3-86853C66C563

P577

Q35023503-FD9DFB27-CC82-4DD9-8BA9-C18111F0FA4C

P698

Q35023503-49EC4235-3ADA-41E0-BB05-830A2985B3B9

P932

Q35023503-6709DFA0-79C1-4FAC-B816-7729E2D9A045

P356

JCO.2010.32.4467

P1433

Journal of Clinical Oncology

P1476

Phase II study of belinostat i ...... nced thymic epithelial tumors.

@en

P2093

Ariel Lopez-Chavez

http://www.w3.org/2001/XMLSchema#string

Arlene Berman

http://www.w3.org/2001/XMLSchema#string

Arun Rajan

http://www.w3.org/2001/XMLSchema#string

Eva Szabo

http://www.w3.org/2001/XMLSchema#string

Giuseppe Giaccone

http://www.w3.org/2001/XMLSchema#string

Igor Espinoza-Delgado

http://www.w3.org/2001/XMLSchema#string

Jane Trepel

http://www.w3.org/2001/XMLSchema#string

John Spittler

http://www.w3.org/2001/XMLSchema#string

Liang Cao

http://www.w3.org/2001/XMLSchema#string

Min-Jung Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

FOXP3+ regulatory T cells in the human immune system

Assays for pharmacodynamic analysis of histone deacetylase inhibitors.

Clinical management of thymoma patients.

Treatment of advanced thymoma and thymic carcinoma.

Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.

Inside HDAC with HDAC inhibitors.

P304

2052-2059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.32.4467

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21502553

http://www.w3.org/2001/XMLSchema#string

P932

3107761

http://www.w3.org/2001/XMLSchema#string